Tosato Marianna, Favaretto Chiara, Kleynhans Janke, Burgoyne Andrew R, Gestin Jean-François, van der Meulen Nicholas P, Jalilian Amirreza, Köster Ulli, Asti Mattia, Radchenko Valery
Radiopharmaceutical Chemistry Laboratory (RACHEL), Nuclear Medicine Unit, AUSL-IRCCS Reggio Emilia, 42123 Reggio Emilia, Italy.
Radiopharmacy and Cyclotron Department, IRCCS Sacro Cuore Don Calabria, Negrar 37024, Verona, Italy.
Nucl Med Biol. 2025 Mar-Apr;142-143:108990. doi: 10.1016/j.nucmedbio.2024.108990. Epub 2024 Dec 20.
Targeted Alpha Therapy has shown great promise in cancer treatment, sparking significant interest over recent decades. However, its broad adoption has been impeded by the scarcity of alpha-emitters and the complexities related to their use. The availability of these radionuclides is often constrained by the intricate production processes and purification, as well as regulatory and logistical challenges. Moreover, the high cost and technical difficulties associated with handling and applying alpha-emitting radionuclides pose additional barriers to their clinical implementation. This Alpha Atlas provides an in-depth overview of the leading alpha-particle emitting radionuclide candidates for clinical use, focusing on their production processes and supply chains. By mapping the current facilities that produce and supply these radionuclides, this atlas aims to assist researchers, clinicians, and industries in initiating or scaling up the applications of alpha-emitters. The Alpha Atlas aspires to act as a strategic guide, facilitating collaboration and driving forward the integration of these potent therapeutic agents into cancer treatment practices.
靶向α治疗在癌症治疗中已显示出巨大的前景，在近几十年引发了极大的关注。然而，其广泛应用受到α发射体稀缺以及与其使用相关的复杂性的阻碍。这些放射性核素的可用性常常受到复杂的生产过程、纯化以及监管和后勤挑战的限制。此外，与处理和应用α发射放射性核素相关的高成本和技术困难为其临床应用带来了额外的障碍。本《α图谱》深入概述了用于临床的主要发射α粒子的放射性核素候选物，重点关注它们的生产过程和供应链。通过绘制当前生产和供应这些放射性核素的设施，本图谱旨在协助研究人员、临床医生和行业启动或扩大α发射体的应用。《α图谱》渴望成为一份战略指南，促进合作并推动将这些强效治疗剂整合到癌症治疗实践中。
